T1	intervention 46 55	Letrozole
T3	total-participants 647 650	112
T4	control 771 788	standard dose arm
T5	outcome-Measure 909 946	suppression in serum estradiol levels
T6	outcome-Measure 1014 1038	changes in serum estrone
T7	outcome-Measure 1040 1052	testosterone
T8	outcome-Measure 1054 1095	C-telopeptide (marker of bone resorption)
T9	outcome-Measure 1097 1110	lipid profile
T10	outcome-Measure 1116 1146	quality-of-life measures (QoL)
T11	outcome 1180 1200	estrogen suppression
T12	outcome 1276 1323	reduction in serum estradiol and estrone levels
T2	eligibility 651 707	postmenopausal women at increased risk for breast cancer
T13	outcome 1397 1428	changes in C-telopeptide levels
T14	outcome 1430 1443	lipid profile
T15	outcome 1445 1464	adverse events (AE)
T16	outcome 1469 1481	QoL measures
